PARAGON-B 2002

A randomised clinical trial investigating the effect of Lamifiban versus placebo in

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>Lamifiban 500μg bolus + 1·0–2·0μg/min infusion (depending on creatinine clearance) ave-fla</th>
</tr>
</thead>
</table>

Control treatment: placebo

Concomitant treatments: -

2 Patients

Patients: -

Inclusion criteria: -

Exclusion criteria: -

3 Methods

Blinding: -

Design: -

Centers: -

Geographical area: -

Sample size: 5225 (2628 / 2597)

ArretTrt1: -

ArretTrt0: -

PeriodInclusion: 1998–99

Hypothese: -
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke (fatal non fatal)</td>
<td>28/2628</td>
<td>15/2597</td>
<td>1.84</td>
<td>[0.98; 3.46]</td>
</tr>
<tr>
<td>Death or myocardial infarction at 5 days</td>
<td>150/2628</td>
<td>159/2597</td>
<td>0.93</td>
<td>[0.74; 1.17]</td>
</tr>
<tr>
<td>Death or myocardial infarction at 30 days</td>
<td>278/2628</td>
<td>296/2597</td>
<td>0.93</td>
<td>[0.78; 1.10]</td>
</tr>
<tr>
<td>Intracranial haemorrhage</td>
<td>2/2628</td>
<td>2/2597</td>
<td>0.99</td>
<td>[0.14; 7.02]</td>
</tr>
<tr>
<td>Major bleed</td>
<td>45/2628</td>
<td>25/2597</td>
<td>1.78</td>
<td>[1.09; 2.91]</td>
</tr>
</tbody>
</table>

5 References

Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002 Jan 22;105:316-21 [11804986]

6 Comments